Protection of human myocardium in vitro by K(ATP) activation with low concentrations of bimakalim

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 1, 1999, Pages 162-172

  Picard, Sandra ^b   Criniti, Anna ^a   Iwashiro, Katsunori ^a   Rouet, René ^b   Monti, Francesco ^a   Tonelli, Euclide ^a   Ruvolo, Giovanni ^a   Ducouret, Pierre ^b   Del Monte, Federica ^a   Papalia, Ugo ^a   Puddu, Paolo Emilio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

ATP dependent potassium channels; Contractility; Human atrium; Hypoxia; Myocardial protection; Reoxygenation

Indexed keywords

BIMAKALIM; DOBUTAMINE; GLIBENCLAMIDE; POTASSIUM CHANNEL;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; FEMALE; HEART ATRIUM CONTRACTILITY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE POTENTIAL; HEART PROTECTION; HUMAN; HUMAN TISSUE; HYPOXIA; INOTROPISM; MALE; PRIORITY JOURNAL; REOXYGENATION;

ADENOSINE TRIPHOSPHATE; ADULT; ANOXIA; BENZOPYRANS; DIHYDROPYRIDINES; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLYBURIDE; HEART ATRIA; HUMANS; ISOMETRIC CONTRACTION; MUSCLE CONTRACTION; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXYGEN; POTASSIUM CHANNELS; TIME FACTORS;

EID: 0033017977     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199907000-00025     Document Type: Article

References (54)

1. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-81.
2. McCullough JR, Normandin DE, Conder ML, Sleph PG, Dzwonczyk S, Grover GJ. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res 1991;69: 949-58.
3. Auchampach JA, Cavero I, Gross GJ. Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol 1992;20:765-71.
4. + channels involves high-energy phosphate preservation. Am J Physiol 1993;265:H1809-18.
5. ATP channels: an endogenous protective mechanism during repetitive ischemia. Am J Physiol 1993;264:H495-504.
6. + channel opener aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther 1991;259:961-7.
7. Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol 1995;25:40-50.
8. Mizumura T, Nithipatikom K, Gross GJ. Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. Cardiovasc Res 1995;29:482-9.
9. Mizumura T, Nithipatikom K, Gross GJ. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation 1995;92:1236-45.
10. ATP channels limits energy depletion in the guinea pig heart. Am J Physiol 1995;269:H734-42.
11. Harding SE, O'Gara P, Jones SM, Brown LA, Vescovo G, Poole-Wilson PA. Species dependence of contraction velocity in single isolated cardiac myocytes. Cardioscience 1990;1:49-54.
12. Galinanes M, Hearse DJ. Species differences in susceptibility to ischemic injury and responsiveness to myocardial protection. Cardioscience 1990;2:127-43.
13. Bers DM. Control of cardiac contraction by SR Ca release and sarcolemmal Ca fluxes. In: Anonymous, ed. Excitation-contraction coupling and cardiac contractile force. Dordrecht: Kluwer Academic Publishers, 1991:149-70.
14. Gautier P, Bertrand JP, Guiraudou P. Effects of SR 44866, a potassium channel opener, on action potentials of rabbit, guinea pig, and human heart fibers. J Cardiovasc Pharmacol 1991;17:692-700.
15. Varrò A, Lathrop DA, Hester SB, Nanasi PP, Papp GY. Ionic currents and action potentials in rabbit, rat, and guinea pig ventricular myocytes. Basic Res Cardiol 1993;88:93-102.
16. Dawodu AA, Monti F, Iwashiro K, Schiariti M, Chiavarelli R, Puddu PE. The shape of human atrial action potential accounts for different frequency-related changes in vitro. Int J Cardiol 1996; 54:237-49.
17. Hearse DJ. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc Res 1995;30:1-17.
18. + channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995;77: 1030-5.
19. Carr CS, Grover GJ, Pugsley WB, Yellon DK. Comparison of the protective effects of a highly selective ATP-sensitive potassium channel opener and ischemic preconditioning in isolated human atrial muscle. Cardiovasc Drugs Ther 1997;11:473-8.
20. + loss and arrhythmias in rat hearts: effect of glibenclamide, a sulfonylurea. Circ Res 1990;66:478-85.
21. + loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 1991;69: 623-37.
22. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769-75.
23. ATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol 1995;26:145-52.
24. Grover GJ, D'Alonzo AJ, Hess T, Sleph PG, Darbenzio RB. Glyburide-reversible cardioprotective effects of BMS-180448 is independent of action potential shortening. Cardiovasc Res 1995;30: 731-8.
25. Di Diego JM, Antzelevitch C. Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues: does activation of ATP-regulated potassium current promote phase 2 reentry? Circulation 1993;88:1177-89.
26. Wilde AAM, Janse MJ. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994;28:16-24.
27. Black SC, Lucchesi BR. Potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc Res 1994; 28:923-4.
28. Sugimoto S, Puddu PE, Monti F, Schiariti M, Campa PP, Marino B. Pretreatment with the adenosine triphosphate-sensitive potassium channel opener nicorandil and improved myocardial protection during high-potassium cardioplegic hypoxia. J Thorac Cardiovasc Surg 1994;108:455-66.
29. + channels enhances myocardial protection due to cold high potassium cardioplegia: a force-frequency relationship study. J Mol Cell Cardiol 1995;27:1867-81.
30. Iwashiro K, Cassese M, Dawodu AA, et al. Stunning in isolated superfused human atrial muscle: protective effects of K-ATP channel activation with bimakalim pretreatment [Abstract]. Circulation 1996;94:I-549.
31. Puddu PE, Picard S, Iwashiro K, et al. Contractile dysfunction following long (60 min) but not repeated shorter (5 min) hypoxia: a stunning model in isolated human atrial muscle. In: Puddu PE, Bing RJ, Campa PP, Poole-Wilson PA, eds. Congestive heart failure: from basic science to therapeutics. Rome: Cardioricerca, 1997:97-120.
32. + cardioplegia. Int J Cardiol 1995;48:11-25.
33. Iwashiro K, Criniti A, Sinatra R, et al. Felodipine protects human atrial muscle from hypoxia-reoxygenation dysfunction: a force-frequency relationship study in an in vitro model of stunning. Int J Cardiol 1997;62:107-32.
34. Shaw RM, Rudy Y. Electrophysiologic effects of acute myocardial ischemia: a theoretical study of altered cell excitability and action potential duration. Cardiovasc Res 1997;35:256-72.
35. + channels. J Biol Chem 1988;263:7933-6.
36. + channels: possible mechanism of cardioprotection. Circ Res 1997;81:1072-82.
37. Escande D, Loisance D, Planché C, Coraboeuf E. Age-related changes of action potential plateau shape in isolated human atrial fibers. Am J Physiol 1985;249:H843-50.
38. Puddu PE, Schiariti M, Chiavarelli R, et al. Nicorandil has different electrophysiologic effects in human as compared to guinea-pig atrial cells [Abstract]. Eur Heart J 1992;13:210.
39. Schiariti M, Puddu PE, Rouet R. Multivariate prediction of spontaneous repetitive responses in ventricular myocardium exposed in vitro to simulated ischemic conditions. Int J Cardiol 1994;45:9-22.
40. Paradise NF, Schmitter JL, Surmitis JM. Criteria for adequate oxygenation of isometric kitten papillary muscle. Am J Physiol 1981; 241:H348-53.
41. Schwinger RHG, Böhm M, Koch A, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res 1994;74: 959-69.
42. St John Sutton MG, Ritman EL, Paradise NF. Biphasic changes in maximum relaxation rate during progressive hypoxia in isometric kitten papillary muscle and isovolumic rabbit ventricle. Circ Res 1980;47:516-24.
43. Dixon WJ. BMDP statistical software manual: to accompany the 7.0 software release. Berkeley: University of California Press, 1992:1-1500.
44. Dixon WJ, Merdian KL. ANOVA and regression with BMDP 5V. Los Angeles: Dixon Statistical Associates, 1992:1-193.
45. Peeters GA, Sanguinetti MC, Eki Y, et al. Method for isolation of human ventricular myocytes from single endocardial and epicardial biopsies. Am J Physiol 1995;268:H1757-64.
46. Bohm M, Diet F, Pieske B, Erdmannn E. Screening of positive inotropic agents in isolated cardiac preparations from different sources. J Pharmacol Methods 1989;21:33-44.
47. Heidbuchel H, Vereecke J, Carmeliet E. Three different potassium channels in human atrium: contribution to the basal potassium conductance. Circ Res 1990;66:1277-86.
48. Ogbaghebriel A, Shrier A. Differential responsiveness of atrial and ventricular myocytes to potassium channel openers. J Cardiovasc Pharmacol 1995;25:65-74.
49. Kida M, Fujiwara H, Uegaito T, et al. Dobutamine prevents both myocardial stunning and phosphocreatine overshoot without affecting ATP level. J Mol Cell Cardiol 1993;25:875-85.
50. ATP) openers in models of myocardial ischemia and reperfusion. J Physiol Pharmacol 1997;75:309-15.
51. + channel from rat liver and beef heart mitochondria. J Biol Chem 1992;267:26062-9.
52. ATP channel as a receptor for potassium channel openers. J Biol Chem 1996;271:8796-9.
53. ATP channel by glyburide and 5-hydroxydecanoate. J Biol Chem 1998;273:13578-82.
54. Liu Y, Sato T, O'Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998;97:2463-9.